While the expression of immune checkpoint markers, such as PD-L1, is generally sparse across different tissue topographies, its elevated levels at metastatic sites suggest an immune evasion mechanism, consistent with observations in other cancer types (20, 21). This evidence concerns the gene CD274 and cancer.